סרטונים אחרונים

בית
מאמרים

Ivermectin and mebendazole, 84% benefit in cancer 121gamers 23 צפיות • לִפנֵי 2 חודשים

Ivermectin and Mebendazole in Cancer Patients

https://zenodo.org/records/19455636

The Clinical Benefit Ratio

Complete Response + Partial Response + Stable Disease / Total Patients

(CBR) was 84.4%

Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year.

Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies.

Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity.

This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol.

Methods:

Prospective observational cohort of 197 cancer patients,

who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers)

Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole.

Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up.

Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed.

A total of 122 participants completed the follow-up survey (61.9% response rate)

Results:

Mean age of 67 years, (52.3% male, 47.7% female).

Cancer types included
Prostate 27.9%
Breast 18.3%
Lung 8.6%
Colon 5.1%
Urologic 4.6%
Pancreatic 3.0%
Liver 2.5%
Gynaecologic 2.5%
Hematologic 2.5%
Median duration since initial diagnosis, 1.2 years

37.1% experiencing active disease progression.

6-month follow-up

Medication adherence, 86.9%

Full initial 90-capsule ivermectin-mebendazole prescription.

The Clinical Benefit Ratio

Complete Response + Partial Response + Stable Disease / Total Patients

(CBR) was 84.4%

Notably, 48.4% of cohort, strongest positive outcomes:

Regression, 15.6%

No current evidence of disease (NED), 32.8%

Disease stability, 36.1%

Disease progression, 15.6%

No significant dose-response association was observed for cancer outcomes (p = 0.91),

without a clear dose-response gradient for efficacy.

Side effects

Mild side effects (primarily gastrointestinal), 25.4%

(93.6% of those affected continued treatment through minor dose adjustments)

Concurrent conventional therapies

Chemotherapy, 27.9%
Radiation therapy, 21.3%
Surgery, 19.7%

Adjunctive interventions such as supplement use, 49.2%
Dietary modification, 37.7%

Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients.

These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit.

However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating.

Urgent prospective, randomized, placebo-controlled clinical trials

Validate these observations and further define optimal dosing strategies.

Mechanism (pharmacodynamics)

Ivermectin and mebendazole are antiparasitic agents,

demonstrated highly promising anti-cancer activity.

Ivermectin

Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types,

inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function.

Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy)

Ivermectin and mebendazole selectively target cancer stem cells

Mebendazole

Microtubule disruption, leading to effective cell cycle arrest

Potent induction of apoptosis

Significant inhibition of tumour growth

Inhibition of angiogenesis

Disruption of glucose uptake

When used together

Target non-overlapping pathways, resulting in synergistic tumour regression,

cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models

Biodistribution, ivermectin and mebendazole document excellent tissue penetration

Ivermectin research 121gamers 23 צפיות • לִפנֵי 2 חודשים

With Professor Colleen Aldous
Critical appraisal of multidrug therapy in the ambulatory
management of patients with COVID-19 and hypoxemia
Part II: Causal inference using the Bradford Hill criteria

https://www.jstage.jst.go.jp/a....rticle/antibiotics/7

We continue the critical appraisal of three published case series of 119 COVID-19 patients with hypoxemia, treated in the United States, Zimbabwe, and Nigeria with similar ivermectin-based multidrug treatments, to assess the available evidence supporting a causal relationship between treatment and reduction in hospitalizations and mortality. A narrative review was conducted to assess the Bradford Hill criteria for a causal association. We used a previously proposed refinement of the Bradford Hill criteria that reorganized them into three categories of direct, mechanistic, and
parallel evidence. The efficacy of the two most aggressive ivermectin-based
multidrug protocols is supported by the Bradford Hill criteria for temporality,
strength of association, biological gradient, biological plausibility, coherence, consistency, and analogy. The causal relation between the treatment of hypoxemic COVID-19 patients using these protocols and the reduction in hospitalizations and mortality is supported as an inference to the best explanation.

Critical appraisal of multidrug therapy in the ambulatory
management of patients with COVID-19 and hypoxemia
Part I. Evidence supporting the strength of association

https://faculty.utrgv.edu/elef....therios.gkioulekas/p

On March 11, 2020, Coronavirus Disease 2019 (COVID-19), the disease caused by the Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization (WHO) [1]. Worldwide, 768,187,096 confirmed cases of COVID-19 and 6,945,714 deaths have been reported to the WHO as of June 21 2023, amounting to an average Case Fatality Rate (CFR) of 0.9% [2]. During 2020, while several governments and public health agencies were focused on contagion control and in-hospital patient care, several medical doctors from all around the world innovated and discovered early outpatient multidrug treatments using several repurposed medications in combination [3–15]. In the United States, several independent efforts coalesced into the formulation of a sequenced multidrug protocol [10, Fig. 3] (hereafter, McCullough protocol), which is based on the pathophysiological understanding of COVID-19 as a triphasic illness with three overlapping phases: (1) viral proliferation; (2) hyperinflammatory cytokine storm (COVID-19 pneumonia); and (3) thrombosis. McCullough’s protocol proposed a combination antiviral therapy for treating the viral proliferation phase, immunomodulators for treating the cytokine storm, and antiplatelet agents and antithrombotics for handling the thrombotic stage, based on risk stratification and how the disease presents in each individual patient. Thus, the McCullough protocol is an algorithmic treatment using sequenced multiple drugs in combination and customized to the individual patient and their response to treatment; no single drug is necessary nor sufficient to achieve treatment efficacy towards reducing hospitalizations and deaths. A recently published update of the McCullough protocol [16, Fig. 3] introduced some adjustments including virucidal nasal washes and oral gargles [17–24]. A large case series of 869 high-risk patients [25, 26], who were treated using an early version of the McCullough protocol, has been compared against population-level and historical controls [27], showing the existence of efficacy with respect to the reduction of mortality and hospitalizations, which is also resilient with respect to random selection bias, provided that patients are treated early enough within the first 3 to 5 days from the onset of illness. Indeed, an earlier study by Fazio et al.[28] showed that the ideal window of opportunity for initiating an effective early outpatient treatment of COVID-19 to prevent hospitalization is approximately within the first 3 days.

Ivermectin PROVEN Effective At Treating Cancer! w/ Nicolas Hulscher 121gamers 3 צפיות • לִפנֵי 2 חודשים

Jimmy speaks with epidemiologist Nicolas Hulscher about an observational study of 200 cancer patients showing that 84.4% benefited from taking ivermectin and fenbendazole for six months, with 32.8% reporting no evidence of disease, 15.6% tumor regression, and 36% cancer stabilization. Hulscher explains that ivermectin targets cancer stem cells—which chemotherapy leaves behind, causing cancer to return—and has over 14 distinct anti-cancer mechanisms across more than 12 cancer types, including inducing apoptosis, cutting off angiogenesis, and disrupting microtubules.

Jimmy shares his personal experience of being vaccine-injured and treated with ivermectin, noting that the medical establishment lied about the drug to fast-track COVID vaccine approval for hundreds of billions in profit. He argues that no government or university will fund randomized trials because ivermectin and fenbendazole cannot be patented, while standard chemotherapy averages $111,000 per year and is highly toxic, something Dr. John Campbell describes as a "complete tragedy" for cancer patients.

Nicolas Hulscher on Twitter: https://twitter.com/nichulscher
Nicolas Hulscher’s Substack: https://www.thefocalpoints.com/

Become a Premium Member: https://www.jimmydore.com/premium-membership
Go to a Live Show: https://www.jimmydore.com/tour
Subscribe to Our Newsletter: https://mailchi.mp/jimmydorecomedy/ytlivestreams

LIVESTREAM & LIVE SHOW ANNOUNCEMENTS:
Email: https://mailchi.mp/jimmydorecomedy/ytlivestreams
Twitter: https://twitter.com/jimmy_dore
Facebook: https://www.facebook.com/JimmyDoreShow
Instagram: https://www.instagram.com/thejimmydoreshow

WATCH / LISTEN FREE:
Videos: https://www.jimmydore.com
Podcasts: https://www.jimmydore.com (Also available on iTunes, Apple Podcasts, Spotify, Google Podcasts, or your favorite podcast player.)

ACCESS TO FULL REPLAYABLE LIVESTREAMS:
Become a Premium Member: https://www.jimmydore.com/premium-membership

SUPPORT THE JIMMY DORE SHOW:
Make a Donation: https://www.jimmydore.com/
Buy Official Merch (Tees, Sweatshirts, Hats, Bags): https://thejimmydoreshow.dashery.com/
https://dobynsfamilycreations.....com/collections/the-

DOWNLOAD OUR MOBILE APP:
App Store: https://apps.apple.com/us/app/....jimmy-dore/id8392945
Google Play: https://play.google.com/store/....apps/details?id=com.

Jimmy Dore on Twitter: https://twitter.com/Jimmy_Dore
Stef Zamorano on Twitter: https://twitter.com/miserablelib

About The Jimmy Dore Show:
#TheJimmyDoreShow is a hilarious and irreverent take on news, politics and culture featuring Jimmy Dore, a professional stand up comedian, author and podcaster. The show is also broadcast on Pacifica Radio Network stations throughout the country.

Joe Rogan was RIGHT about ivermectin 🤯 121gamers 1 צפיות • לִפנֵי 2 חודשים

#DrJoshAxe #holistichealth #DrAxe #Viral #ViralShorts #BiblioDiet #Health
#joerogan #rfkjr #ivermectin

Order Dr. Josh Axe & Jordan Rubin's NEW BOOK, The Biblio Diet, TODAY → https://www.christianbook.com/....biblio-diet-transfor

SUBSCRIBE FOR MORE: https://www.youtube.com/c/DrJo....shAxe?sub_confirmati
--------------------
CONNECT WITH DR. JOSH AXE
Like on Facebook → facebook.com/drjoshaxe/
Follow on Instagram → instagram.com/drjoshaxe/
Follow on Twitter → twitter.com/drjoshaxe/
Follow on TikTok → tiktok.com/@drjoshaxe/
--------------------
ABOUT DR. JOSH AXE
Dr. Josh Axe, DC, DNM, CNS, is a doctor of chiropractic, certified doctor of natural medicine, clinical nutritionist, leadership expert and highly successful entrepreneur, with a passion to help people eat healthy and live a healthy lifestyle. He earned his doctorate from Palmer College and his Master of Science in Organizational Leadership from Johns Hopkins University. Dr. Axe is the cofounder and CVO of Ancient Nutrition, founder of DrAxe.com, and founder of The Health Institute. His businesses have ranked on the Inc. 500 fastest growing companies. He is the bestselling author of Think This Not That, Eat Dirt, Keto Diet, and Ancient Remedies. He regularly teaches lectures and trains entrepreneurs on leadership, mindset, and self- development. Josh is married to his wife, Chelsea, and they have two daughters. They live between Nashville, TN and Dorado, PR and enjoy cooking, staying active swimming and cycling, and prioritize time for their faith and family.
--------------------
DISCLAIMER
This content is strictly the opinion of Dr. Josh Axe and is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of medical advice or treatment from a personal physician. All viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. Neither Dr. Axe nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this educational content. All viewers of this content, especially those taking prescription or over-the-counter medications, should consult their physicians before beginning any nutrition, supplement or lifestyle program.

Showing 48 out of 49

שים לב שאם אתה מתחת לגיל 18, לא תוכל לגשת לאתר זה.

סרטונים אחרונים

שפה